Elevation of high-mobility group box 1 after clinical autologous islet transplantation and its inverse correlation with outcomes

Cell Transplantation

Volumn 23, Issue 2, 2014, Pages 153-165

  Itoh, Takeshi ^a   Iwahashi, Shuichi ^a   Kanak, Mazhar A ^b   Shimoda, Masayuki ^a   Takita, Morihito ^a   Chujo, Daisuke ^c   Tamura, Yoshiko ^d   Rahman, Ana M ^d   Chung, Wen Y ^e   Onaca, Nicholas ^d   Coates, P Toby H ^f   Dennison, Ashley R ^e   Naziruddin, Bashoo ^d   Levy, Marlon F ^d   Matsumoto, Shinichi ^a  

^a BAYLOR RESEARCH INSTITUTE   (United States)

^b BAYLOR UNIVERSITY   (United States)

^c BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^f ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Autologous islet transplantation (AIT); Chronic pancreatitis; High mobility group box 1 (HMGB1); Islets; Pancreatectomy

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; C PEPTIDE; EOTAXIN; EPIDERMAL GROWTH FACTOR; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOGLOBIN A1C; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PROINSULIN; VASCULOTROPIN;

ADULT; ANTIGEN RETRIEVAL; ARTICLE; AUTOTRANSPLANTATION; CELL DAMAGE; CHRONIC PANCREATITIS; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HORMONE RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; INFUSION; LEUKOCYTE COUNT; MALE; OUTCOME ASSESSMENT; PANCREAS ISLET TRANSPLANTATION; PANCREAS RESECTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; ANIMALS; FEMALE; HMGB1 PROTEIN; HUMANS; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; MICE; MIDDLE AGED; PANCREATECTOMY; PANCREATITIS, CHRONIC; RECEPTORS, IMMUNOLOGIC;

EID: 84893326706     PISSN: 09636897     EISSN: None     Source Type: Journal    
DOI: 10.3727/096368912X658980     Document Type: Article

References (39)

1. Ahmad, S. A.; Lowy, A. M.; Wray, C. J.; D'Alessio, D.; Choe, K. A.; James, L. E.; Gelrud, A.; Matthews, J. B.; Rilo, H. L. Factors associated with insulin and narcotic independence after islet autotransplantation in patients with severe chronic pancreatitis. J. Am. Coll. Surg. 201:680-687; 2005.
2. Arabi, Y. M.; Dehbi, M.; Rishu, A. H.; Baturcam, E.; Kahoul, S. H.; Brits, R. J.; Naidu, B.; Bouchama, A. sRAGE in diabetic and non-diabetic critically ill patients: Effects of intensive insulin therapy. Crit. Care 15:R203; 2011.
3. Braganza, J. M.; Lee, S. H.; McCloy, R. F.; McMahon, M. J. Chronic pancreatitis. Lancet 377:1184-1197; 2011.
4. Bucciarelli, L. G.; Wendt, T.; Qu, W.; Lu, Y.; Lalla, E.; Rong, L. L.; Goova, M. T.; Moser, B.; Kislinger, T.; Lee, D. C.; Kashyap, Y.; Stern, D. M.; Schmidt, A. M. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106:2827-2835; 2002.
5. Chavakis, T.; Bierhaus, A.; Nawroth, P. P. RAGE (receptor for advanced glycation end products): A central player in the inflammatory response. Microbes Infect. 6:1219-1225; 2004.
6. Clayton, H. A.; Davies, J. E.; Pollard, C. A.; White, S. A.; Musto, P. P.; Dennison, A. R. Pancreatectomy with islet autotransplantation for the treatment of severe chronic pancreatitis: The first 40 patients at the Leicester general hospital. Transplantation 76:92-98; 2003.
7. Dumitriu, I. E.; Baruah, P.; Valentinis, B.; Voll, R. E.; Herrmann, M.; Nawroth, P. P.; Arnold, B.; Bianchi, M. E.; Manfredi, A. A.; Rovere-Querini, P. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J. Immunol. 174:7506-7515; 2005.
8. Falcone, C.; Emanuele, E.; D'Angelo, A.; Buzzi, M. P.; Belvito, C.; Cuccia, M.; Geroldi, D. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler. Thromb. Vasc. Biol. 25:1032-1037; 2005.
9. Gardella, S.; Andrei, C.; Ferrera, D.; Lotti, L. V.; Torrisi, M. R.; Bianchi, M. E.; Rubartelli, A. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep. 3:995-1001; 2002.
10. Itoh, T.; Iwahashi, S.; Shimoda, M.; Chujo, D.; Takita, M.; Sorelle, J. A.; Naziruddin, B.; Levy, M. F.; Matsumoto, S. High-mobility group box 1 expressions in hypoxia-induced damaged mouse islets. Transplant. Proc. 43:3156-3160; 2011.
11. Itoh, T.; Sugimoto, K.; Takita, M.; Shimoda, M.; Chujo, D.; SoRelle, A. J.; Naziruddin, B.; Levy, M. F.; Matsumoto, S. Low temperature condition prevent hypoxia-induced islet cell damage and HMGB1 release in a mouse model. Cell Transplant. 21(7):1361-1370; 2012.
12. Itoh, T.; Takita, M.; SoRelle, A. J.; Shimoda, M.; Sugimoto, K.; Chujo, D.; Qin, H.; Naziruddin, B.; Levy, M. F.; Matsumoto, S. Correlation of released HMGB1 levels with the degree of islet damage in mice and humans and with the outcomes of islet transplantation in mice. Cell Transplant. 21(7):1371-1381; 2012.
13. Kohno, T.; Anzai, T.; Shimizu, H.; Kaneko, H.; Sugano, Y.; Yamada, S.; Yoshikawa, T.; Ishizaka, A.; Yozu, R.; Ogawa, S. Impact of serum high-mobility group box 1 protein elevation on oxygenation impairment after thoracic aortic aneurysm repair. Heart Vessels 26:306-312; 2011.
14. Koyama, H.; Yamamoto, H.; Nishizawa, Y. RAGE and soluble RAGE: Potential therapeutic targets for cardiovascular diseases. Mol. Med. 13:625-635; 2007.
15. Lindsey, J. B.; de Lemos, J. A.; Cipollone, F.; Ayers, C. R.; Rohatgi, A.; Morrow, D. A.; Khera, A.; McGuire, D. K. Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: Observations from the Dallas Heart Study. Diabetes Care 32:1218-1220; 2009.
16. Lotze, M. T.; Tracey, K. J. High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal. Nat. Rev. Immunol. 5:331-342; 2005.
17. Malherbe, P.; Richards, J. G.; Gaillard, H.; Thompson, A.; Diener, C.; Schuler, A.; Huber, G. cDNA cloning of a novel secreted isoform of the human receptor for advanced glycation end products and characterization of cells coexpressing cell-surface scavenger receptors and Swedish mutant amyloid precursor protein. Brain Res. Mol. Brain Res. 71:159-170; 1999.
18. Matsumoto, S. Autologous islet cell transplantation to prevent surgical diabetes. J. Diabetes 3:328-336; 2011.
19. Matsumoto, S.; Noguchi, H.; Naziruddin, B.; Onaca, N.; Jackson, A.; Nobuyo, H.; Okitsu, T.; Kobayashi, N.; Klintmalm, G.; Levy, M. F. Improvement of pancreatic islet cell isolation for transplantation. Proc. Bayl. Univ. Med. Cent. 20:357-362; 2007.
20. Matsumoto, S.; Noguichi, H.; Shimoda, M.; Ikemoto, T.; Naziruddin, B.; Jackson, A.; Tamura, Y.; Olson, G.; Fujita, Y.; Chujo, D.; Takita, M.; Kobayashi, N.; Onaca, N.; Levy, M. F. Seven consecutive successful clinical islet isolations with pancreatic ductal injection. Cell Transplant. 19:291-297; 2010.
21. Matsumoto, S.; Okitsu, T.; Iwanaga, Y.; Noguchi, H.; Nagata, H.; Yonekawa, Y.; Yamada, Y.; Fukuda, K.; Shibata, T.; Kasai, Y.; Maekawa, T.; Wada, H.; Nakamura, T.; Tanaka, K. Successful islet transplantation from nonheart beating donor pancreata using modified Ricordi islet isolation method. Transplantation 82:460-465; 2006.
22. Matsumoto, S.; Rigley, T. H.; Qualley, S. A.; Kuroda, Y.; Reems, J. A.; Stevens, R. B. Efficacy of the oxygen-charged static two-layer method for short-term pancreas preservation and islet isolation from nonhuman primate and human pancreata. Cell Transplant. 11:769-777; 2002.
23. Matsuoka, N.; Itoh, T.; Watarai, H.; Sekine-Kondo, E.; Nagata, N.; Okamoto, K.; Mera, T.; Yamamoto, H.; Yamada, S.; Maruyama, I.; Taniguchi, M.; Yasunami, Y. High-mobility group box 1 is involved in the initial events of early loss of transplanted islets in mice. J. Clin. Invest. 120:735-743; 2010.
24. Muhammad, S.; Barakat, W.; Stoyanov, S.; Murikinati, S.; Yang, H.; Tracey, K. J.; Bendszus, M.; Rossetti, G.; Nawroth, P. P.; Bierhaus, A.; Schwaninger, M. The HMGB1 receptor RAGE mediates ischemic brain damage. J. Neurosci. 28:12023-12031; 2008.
25. Müller, S.; Ronfani, L.; Bianchi, M. E. Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J. Intern. Med. 255:332-343; 2004.
26. Ricordi, C.; Lacy, P. E.; Scharp, D. W. Automated islet isolation from human pancreas. Diabetes 38(Suppl 1):140-142; 1989.
27. Robertson, R. P.; Lanz, K. J.; Sutherland, D. E.; Kendall, D. M. Prevention of diabetes for up to 13 years by autoislet transplantation after pancreatectomy for chronic pancreatitis. Diabetes 50:47-50; 2001.
28. Saldeen, J. Cytokines induce both necrosis and apoptosis via a common Bcl-2-inhibitable pathway in rat insulin-producing cells. Endocrinology 141:2003-2010; 2000.
29. Schlueter, C.; Hauke, S.; Flohr, A. M.; Rogalla, P.; Bullerdiek, J. Tissue-specific expression patterns of the RAGE receptor and its soluble forms-A result of regulated alternative splicing? Biochim. Biophys. Acta 1630:1-6; 2003.
30. Semino, C.; Angelini, G.; Poggi, A.; Rubartelli, A. NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. Blood 106:609-616; 2005.
31. Seong, S. Y.; Matzinger, P. Hydrophobicity: An ancient damage-associated molecular pattern that initiates innate immune responses. Nat. Rev. Immunol. 4:469-478; 2004.
32. Sims, G. P.; Rowe, D. C.; Rietdijk, S. T.; Herbst, R.; Coyle, A. J. HMGB1 and RAGE in inflammation and cancer. Annu. Rev. Immunol. 28:367-388; 2010.
33. Soro-Paavonen, A.; Watson, A. M.; Li, J.; Paavonen, K.; Koitka, A.; Calkin, A. C.; Barit, D.; Coughlan, M. T.; Drew, B. G.; Lancaster, G. I.; Thomas, M.; Forbes, J. M.; Nawroth, P. P.; Bierhaus, A.; Cooper, M. E.; Jandeleit-Dahm, K. A. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 57:2461-2469; 2008.
34. Suda, K.; Kitagawa, Y.; Ozawa, S.; Saikawa, Y.; Ueda, M.; Abraham, E.; Kitajima, M.; Ishizaka, A. Serum concentrations of high-mobility group box chromosomal protein 1 before and after exposure to the surgical stress of thoracic esophagectomy: A predictor of clinical course after surgery? Dis. Esophagus 19:5-9; 2006.
35. Teuscher, A. U.; Kendall, D. M.; Smets, Y. F.; Leone, J. P.; Sutherland, D. E.; Robertson, R. P. Successful islet autotransplantation in humans: Functional insulin secretory reserve as an estimate of surviving islet cell mass. Diabetes 47:324-330; 1998.
36. Wang, H.; Bloom, O.; Zhang, M.; Vishnubhakat, J. M.; Ombrellino, M.; Che, J.; Frazier, A.; Yang, H.; Ivanova, S.; Borovikova, L.; Manogue, K. R.; Faist, E.; Abraham, E.; Andersson, J.; Andersson, U.; Molina, P. E.; Abumrad, N. N.; Sama, A.; Tracey, K. J. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285:248-251; 1999.
37. Yamada, S.; Maruyama, I. HMGB1, a novel inflammatory cytokine. Clin. Chim. Acta 375:36-42; 2007.
38. Yonekura, H.; Yamamoto, Y.; Sakurai, S.; Petrova, R. G.; Abedin, M. J.; Li, H.; Yasui, K.; Takeuchi, M.; Makita, Z.; Takasawa, S.; Okamoto, H.; Watanabe, T.; Yamamoto, H. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem. J. 370:1097-1109; 2003.
39. Yujiri, T.; Tagami, K.; Tanaka, Y.; Mitani, N.; Nakamura, Y.; Ariyoshi, K.; Ando, T.; Tanizawa, Y. Increased serum levels of high-mobility group box 1 protein in patients who developed acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Eur. J. Haematol. 85:366-367; 2010.